Skip to Content

Optimark

Active Substance: gadoversetamide
Common Name: gadoversetamide
ATC Code: V08CA06
Marketing Authorisation Holder: Mallinckrodt Deutschland GmbH
Active Substance: gadoversetamide
Status: Withdrawn
Authorisation Date: 2007-07-23
Therapeutic Area: Magnetic Resonance Imaging
Pharmacotherapeutic Group: Contrast media

Therapeutic Indication

This medicinal product is for diagnostic use only.

Optimark is indicated for use with magnetic resonance imaging (MRI) of the central nervous system (CNS) and liver. It provides contrast enhancement and facilitates visualisation and helps with the characterisation of focal lesions and abnormal structures in the CNS and liver in patients with known or highly suspected pathology.

The marketing authorisation for Optimark has been withdrawn at the request of the marketing authorisation holder.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Hide